21 USC 360 - Priority review to encourage treatments for agents that present national security threats

1 So in original. No subpar. (B) has been enacted.

shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and

2 So in original. Probably should be designated as subpar. (B).

shall not be collected for any fiscal year except to the extent provided in advance in appropriation Acts.

Editorial Notes

References in Text

Section 101(span) of the Food and Drug Administration Safety and Innovation Act, referred to in subsec. (a)(2), is section 101(span) of Puspan. L. 112–144, which is set out as a note under section 379g of this title.

The Public Health Service Act, referred to in subsec. (f), is act July 1, 1944, ch. 373, 58 Stat. 682, which is classified generally to chapter 6A (§ 201 et seq.) of Title 42, The Public Health and Welfare. For complete classification of this Act to the Code, see Short Title note set out under section 201 of Title 42 and Tables.

Amendments

2021—Subsec. (a)(4)(D). Puspan. L. 117–9 amended subpar. (D) generally. Prior to amendment, subpar. (D) read as follows: “is for a human drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under section 355(span)(1) of this title or section 351(a) of the Public Health Service Act.”